Advanced in Relapsing Multiple Sclerosis (RMS)

Refik Pul

Carl Neuberg Str. 1, 
Hannover, NI, DE 
Advanced in Relapsing Multiple Sclerosis (RMS)
Carl Neuberg Str. 1, 
Hannover, NI, DE 
OverviewLocationsClinical Research

Overview

Refik Pul practices in Hannover, Germany. Pul is rated as an Advanced expert by MediFind in the treatment of Relapsing Multiple Sclerosis (RMS). Their top areas of expertise are Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), Optic Neuritis, and Transverse Myelitis.

Their clinical research consists of co-authoring 101 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 24 articles and participated in 3 clinical trials in the study of Relapsing Multiple Sclerosis (RMS).

Locations

Carl Neuberg Str. 1, Hannover, NI 30625, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
Enrollment Status: Completed
Publish Date: March 16, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
Enrollment Status: Terminated
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Enrollment Status: Terminated
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

101 Total Publications

Switching from anti-CD20 therapies to cladribine and vice versa - Analysis of a German relapsing multiple sclerosis cohort.
Switching from anti-CD20 therapies to cladribine and vice versa - Analysis of a German relapsing multiple sclerosis cohort.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: September 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Pul's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile